IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
This study is ongoing, but not recruiting participants.
Sponsor:
Showa Inan General Hospital
Information provided by (Responsible Party):
Akira Horiuchi, Showa Inan General Hospital
ClinicalTrials.gov Identifier:
NCT00596401
First received: January 8, 2008
Last updated: April 28, 2017
Last verified: April 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Recently, the preventive effect of Helicobacter pylori (Hp) eradication treatment on the incidence of gastric cancer has been reported. By Hp eradication treatment being performed for Hp-infected people in Iijima town, we will evaluate whether the incidence of gastric cancer and/or the medical care cost can be reduced as compared with those in the previous years.
| Condition |
|---|
| Helicobacter Pylori Eradication Gastric Cancer Medical Care Cost |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer and the Medical Care Cost in Iijima Town |
Resource links provided by NLM:
Further study details as provided by Akira Horiuchi, Showa Inan General Hospital:
Primary Outcome Measures:
- the annual incidence of gastric cancer in Iijima town [ Time Frame: 10 years ]
Secondary Outcome Measures:
- The annual medical care cost in Iijima town [ Time Frame: 10 years ]
Biospecimen Retention: Samples Without DNA
serum
| Enrollment: | 3000 |
| Study Start Date: | September 2007 |
| Estimated Study Completion Date: | August 2017 |
| Estimated Primary Completion Date: | August 2017 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
HP eradication group
|
|
2
No eradication group
|
|
3
No Hp group
|
Eligibility| Ages Eligible for Study: | 19 Years to 69 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
People who live in Iijima town
Criteria
Inclusion Criteria:
- People who live in Iijima town at their age of 19 to 69 years
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00596401
Please refer to this study by its ClinicalTrials.gov identifier: NCT00596401
Locations
| Japan | |
| Showa Inan General hospital | |
| Komagane, Nagano, Japan, 399-4191 | |
Sponsors and Collaborators
Showa Inan General Hospital
Investigators
| Study Director: | Akira Horiuchi, M.D. | Showa Inan General Hospital |
More Information
| Responsible Party: | Akira Horiuchi, Digestive Disease Center, Showa Inan General Hospital |
| ClinicalTrials.gov Identifier: | NCT00596401 History of Changes |
| Other Study ID Numbers: |
sihp20076 |
| Study First Received: | January 8, 2008 |
| Last Updated: | April 28, 2017 |
Additional relevant MeSH terms:
|
Stomach Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Stomach Diseases |
ClinicalTrials.gov processed this record on August 18, 2017